Welcome to our dedicated page for Artelo Biosciences news (Ticker: ARTL), a resource for investors and traders seeking the latest updates and insights on Artelo Biosciences stock.
Artelo Biosciences, Inc. (NASDAQ: ARTL) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with an additional office in Dublin, Ireland. The company is dedicated to the development and commercialization of proprietary therapeutics that modulate lipid signaling pathways, including the endocannabinoid system. Artelo leverages past research and cutting-edge science to accelerate the development of a diverse portfolio of novel therapeutics with the potential to dramatically improve patient care in major markets.
Core to Artelo's mission is their focus on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. This includes cannabinoid-based therapies, both derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The company's flagship program is a patent-protected cannabinoid drug combination treatment aimed at rare and orphan diseases.
One of their notable projects, ART12.11, has demonstrated improved bioavailability of CBD in both fed and fasted states compared to CBD alone. This proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP) offers biopharmaceutic advantages over standard CBD compositions, showing better pharmacokinetics and improved efficacy in preclinical studies. The US-issued composition of matter patent for ART12.11 is enforceable until December 10, 2038.
Another significant program is ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor being developed as a non-opioid, non-steroidal analgesic for chemotherapy-induced peripheral neuropathy (CIPN) and potentially other neuropathic pains. ART26.12 has shown promising results in preclinical studies, reducing pain in models of diabetic neuropathy and chemotherapy-induced peripheral neuropathy.
Artelo is also advancing ART27.13, a G-Protein Coupled Receptor (GPCR) agonist targeting CB1 and CB2 receptors. This program is currently in the Cancer Appetite Recovery Study (CAReS) Phase 2a trial, aimed at improving body weight, appetite, muscle degeneration, and quality of life in cancer patients. The company has reported positive progress in clinical trials and aims to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation.
Led by experienced biopharmaceutical executives and backed by collaborations with highly respected researchers and technology experts, Artelo applies rigorous scientific, regulatory, and commercial discipline to develop high-impact therapies. The company maintains a strong presence in global biopharma innovation hubs, ensuring close access to world-class research expertise.
Artelo Biosciences (ARTL) presented Phase 1 data from the CAReS trial for ART27.13, their investigational drug for cancer-related anorexia. The trial demonstrated promising results with two-thirds of participants showing stabilized or reversed weight loss after one month of treatment. The drug was well-tolerated with only mild to moderate adverse events in a minority of participants, with no serious adverse events recorded.
The Phase 2 portion of the trial is currently enrolling participants across fifteen sites in five countries, administering 650 microgram doses with planned escalation up to 1300 micrograms daily. The study will evaluate endpoints including lean body mass, weight gain, quality of life, and safety, with completion expected in the first half of 2025.
Artelo Biosciences (NASDAQ: ARTL) announced its participation in the 7th Cannabinoid-Derived Drug Development Summit, taking place November 18-20, 2024, in Boston. Professor Saoirse O'Sullivan, VP of Translational Sciences, will present key data from three development programs:
1. FABP5 Inhibitors as Novel Therapeutics (ART26.12)
2. ART27.13: A Peripherally Selective CB1/CB2 Agonist for Cancer Cachexia
3. ART12.11: A Novel Cannabidiol Cocrystal comparable to Epidiolex®
The presentations aim to explore business development and collaboration opportunities, showcasing how lipid modification can address serious medical conditions with treatment options.
Artelo Biosciences (ARTL) presented new data on ART26.12, their lead clinical Fatty Acid Binding Protein 5 (FABP5) inhibitor, for osteoarthritis (OA) pain treatment. In preclinical studies at Stony Brook University, ART26.12 showed superior symptom relief compared to naproxen in a surgical rodent OA model, demonstrating significant improvement in weight-bearing across all tested doses. The compound exhibited a clear dose-response relationship, with higher concentrations providing better pain relief.
The FDA has cleared ART26.12 for its first-in-human Phase 1 single ascending dose study, with initial results expected in H1 2025. The treatment targets over 500 million people globally affected by OA, according to WHO, and represents a potential alternative to NSAIDs and opioids.
Artelo Biosciences (NASDAQ: ARTL) reported Q3 2024 financial results and provided updates on its clinical pipeline. The company ended the quarter with $4.9 million in cash and investments. Net loss was $1.1 million ($0.35 per share), compared to $2.4 million in Q3 2023. R&D expenses decreased to $0.3 million from $1.6 million year-over-year. The company received $1.3 million in R&D tax credits from the UK government.
Multiple clinical readouts are expected over the next 15 months. The Phase 2 CAReS trial for ART27.13 in cancer-related anorexia is expected to complete enrollment in early 2025. FDA clearance was received for ART26.12 trials in chemotherapy-induced peripheral neuropathy, with Phase 1 results expected in H1 2025. ART12.11 clinical trials for anxiety and depression are planned for 2025.
Artelo Biosciences (Nasdaq: ARTL) announced that its lead clinical FABP inhibitor, ART26.12, has been accepted into the NIH's Preclinical Screening Platform for Pain (PSPP) program, part of the HEAL Initiative. The PSPP program evaluates non-opioid assets in preclinical pain models and is open to researchers globally. The HEAL Initiative aims to address the overdose epidemic and pain crisis by improving prevention, treatment strategies, and pain management. Artelo previously received FDA clearance for first-in-human studies of ART26.12, with initial results expected in the first half of 2025.
Artelo Biosciences, a clinical-stage pharmaceutical company focusing on lipid-signaling pathways for various medical conditions, announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The event is scheduled for October 15-17, 2024.
CEO Gregory D. Gorgas will engage in a fireside chat with Jason McCarthy, Maxim's Senior MD and Head of Biotechnology Research analyst, on Wednesday, October 16, 2024, at 4:00 p.m. ET. Interested parties can access the webcast by registering at the provided link.
Artelo Biosciences (Nasdaq: ARTL) focuses on developing treatments for people living with cancer, pain, dermatologic and neurological conditions. This participation offers an opportunity for investors and interested parties to gain insights into the company's progress and future plans.
Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024, in New York City. CEO Gregory D. Gorgas will represent the company, with an on-demand presentation available to registered attendees starting September 9 at 7:00 AM Eastern Time.
The presentation will be accessible via webcast on the conference platform and Artelo's investor relations website. Management will also engage in one-on-one meetings with qualified investors throughout the conference. Artelo focuses on modulating lipid-signaling pathways to develop treatments for cancer, pain, and dermatologic and neurological conditions.
Artelo Biosciences (Nasdaq: ARTL) reported its Q2 2024 financial results and provided a business update. The company is entering a productive phase in clinical development, with multiple readouts expected over the next 18 months. Key highlights include:
- FDA clearance to initiate clinical trials for ART26.12 for chemotherapy-induced peripheral neuropathy
- Anticipated full enrollment in Phase 2a of the CAReS trial for ART27.13 by early 2025
- ART12.11 in final stages of product formulation, potential clinical study entry in early 2025
Financially, Artelo reported $5.6 million in cash and cash equivalents as of June 30, 2024, with an additional $1.3 million received from UK R&D tax credits in July. Q2 2024 net loss was $2.4 million, or $0.75 per share, compared to $1.6 million, or $0.56 per share, in Q2 2023.
Artelo Biosciences (Nasdaq: ARTL) has received FDA clearance for its Investigational New Drug (IND) application for ART26.12, a selective Fatty Acid Binding Protein 5 (FABP5) inhibitor. This clearance allows Artelo to initiate a Phase 1 single ascending dose study for chemotherapy-induced peripheral neuropathy (CIPN), a condition with no FDA-approved treatment. ART26.12 is being developed as a non-opioid approach to manage painful neuropathies. The company expects Phase 1 trial results in the first half of 2025. Artelo's FABP inhibitor platform has attracted interest from potential partners due to its preclinical efficacy, novel mechanism, and strong patent estate.
Artelo Biosciences presented comparative preclinical data on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium. Findings revealed ART12.11, a novel cannabidiol: tetramethylpyrazine cocrystal, has a unique pharmacokinetic profile, potentially superior to existing treatments for anxiety-related disorders. Research showed ART12.11 increased plasma levels of CBD in rodents and displayed efficacy in reducing anxiety and depressive symptoms. The drug demonstrated similar plasma levels of CBD as Epidiolex, suggesting its potential as an effective treatment. Artelo is currently optimizing ART12.11's oral delivery formulation.
FAQ
What is the current stock price of Artelo Biosciences (ARTL)?
What is the market cap of Artelo Biosciences (ARTL)?
What does Artelo Biosciences do?
Where is Artelo Biosciences headquartered?
What are the main therapeutic areas Artelo Biosciences focuses on?
What is ART12.11?
What is ART26.12?
What is ART27.13?
What recent achievement has ART12.11 demonstrated?
What progress has been made in the ART26.12 program?
Who leads Artelo Biosciences?
Where can I find more information about Artelo Biosciences?
